4883.T
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.
Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.
The company maintains a strong liquidity position, with cash and equivalents amounting to ¥2.81 billion, significantly exceeding its total liabilities of ¥170.95 million, resulting in a current ratio of 21.46. The absence of long-term debt and a debt-to-equity ratio of 0.0 further underscore its robust capital structure. However, the company reported negative returns on equity and assets of -7.71% and -7.26%, respectively, indicating poor profitability and returns relative to its equity and asset base.
The company's financial performance is marked by a net loss of ¥2.15 billion and an operating loss of ¥2.21 billion, with no revenue reported in the latest period. These figures suggest a challenging operating environment and a lack of revenue generation, which is a concern given the industry's preference for metrics such as revenue growth and operating margins. The company's performance is significantly below the industry median for profitability and returns, highlighting a need for strategic improvements in its operations and revenue streams.
The company's revenue concentration is not disclosed in the available data, but the absence of revenue in the latest period suggests a potential over-reliance on a few products or markets, which could pose a risk to its financial stability. The lack of revenue also indicates a possible disruption in its business model or market conditions affecting its ability to generate income.
The company's growth trajectory is currently negative, with a net loss and no revenue reported. The absence of revenue and the significant operating loss suggest a decline in business performance, which could impact its future growth prospects. The company's capital expenditure of ¥2.57 million indicates minimal investment in new projects or expansion, which may limit its ability to drive future revenue growth.
The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The absence of long-term debt and a strong cash position further support the low liquidity risk. However, the company's poor profitability and lack of revenue could pose long-term risks to its financial stability.
Recent financial filings and transcripts do not provide additional insights into the company's operations or strategic direction. The lack of revenue and the significant net loss suggest potential challenges in the company's business model or market conditions that require further investigation.
- The company has a strong liquidity position with a current ratio of 21.46 and no long-term debt.
- The company reported a net loss of ¥2.15 billion and an operating loss of ¥2.21 billion, with no revenue in the latest period.
- The company's return on equity and assets are negative, indicating poor profitability and returns.
- The company's growth trajectory is negative, with no revenue and a significant operating loss.
- The company's risk assessment indicates low liquidity and dilution risks, but its financial performance is a concern.
- "margin_outlook_rationale": "The company's operating margin is negative, indicating poor cost control and pricing power.",
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- 4883.T Market data — financials · 2026-05-26
- Modalis Therapeutics Corp Market data — analyst estimates · 2026-05-26